Evidence map›Paper›PMID 34107236›Full record

ArticleAmerican journal of respiratory and critical care medicine2021

Multiple Manifestations of Systemic Sclerosis Affect Walk Distance.

Kristofer Andréasson, Maria F Bengtsson, Carina Boström, Roger Hesselstrand, Elizabeth R Volkmann

Registry-linked trialAbstract readLetterComment
In one paragraph

Article in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01086540 (A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01086540 phase2completednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2011 to 2019Enrolled57ConditionsSystemic Sclerosis-Associated PAHArmsRituximab, Placebo, CMRI, prednisone, methylprednisolone
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Kristofer AndréassonLund University Lund, Sweden.
Maria F BengtssonLund University Lund, Sweden.
Carina BoströmKarolinska Institute Stockholm, Sweden.
Roger HesselstrandLund University Lund, Sweden.
Elizabeth R VolkmannUniversity of California, Los Angeles Los Angeles, California.ORCID 0000-0003-3750-6569

Funding

Identifying predictors of treatment response in systemic sclerosis-related interstitial lung diseaseK23HL150237 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOLKMANN, ELIZABETH R · 2020 to 2024
$910k
NHLBI NIH HHS K23 HL150237
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Scleroderma, SystemicWalkingHumans

Identifiers

PMID34107236
PMCPMC8513583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.